Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNK01 + Trastuzumab/Cetuximab in Advanced HER2/EGFR Cancers
NCT04464967Phase 2Withdrawn
- Sponsor
- NKGen Biotech
- Start
- Mar 2021
- Primary completion
- Aug 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
A Phase 2 trial of troculeucel in HER2-positive breast cancer, gastric cancer (GC), esophageal cancer, ovarian cancer, endometrial cancer (EC), sponsored by NKGen Biotech. Planned start Mar 2021; status: withdrawn.
02
Drugs
troculeucel
03
Conditions
HER2-positive breast cancergastric cancer (GC)esophageal cancerovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT04464967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464967.